Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is a direct-acting, reversible P2Y12 platelet inhibitor. It is indicated to reduce the thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
## Primary Indications
* Reduction of thrombotic cardiovascular events in patients with ACS.
* Reduction of thrombotic cardiovascular events in patients with a history of MI (at least 1 year prior) and at high risk for an aterothrombotic event.
## Adult Dosing
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily for the first 12 months of treatment in ACS patients. After 12 months, 60 mg orally twice daily may be considered for patients with a history of MI at high risk for an atherothrombotic event.
* **Dosing for Patients with History of MI:** 60 mg orally twice daily.
## Pediatric Dosing
* Safety and efficacy in pediatric patients have not been established.
## Dose Adjustments
* No dose adjustment is required for patients with mild to severe renal impairment or moderate to severe hepatic impairment.
## Contraindications
* Active pathological bleeding.
* History of intracranial hemorrhage.
* Hypersensitivity to ticagrelor or any of its components.
## Adverse Effects
* **Common:** Dyspnea, bradycardia, non-valvular bleeding (e.g., bruising, epistaxis, gingival bleeding), diarrhea.
* **Serious:** Major bleeding, including fatal bleeding. Ventricular pauses.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Strong inhibitors (e.g., ketoconazole, clarithromycin) can increase ticagrelor levels; strong inducers (e.g., rifampin, carbamazepine) can decrease levels.
* **CYP3A4 Substrates:** Ticagrelor can increase concentrations of CYP3A4 substrates (e.g., simvastatin, atorvastatin).
* **P-glycoprotein (P-gp) Inhibitors/Substrates:** Ticagrelor is a P-gp substrate. Co-administration with strong P-gp inhibitors may increase ticagrelor concentrations.
* **Other Antiplatelets/Anticoagulants:** Increased risk of bleeding.
## Monitoring
* Monitor for signs and symptoms of bleeding.
* Monitor for bradycardia; consider ECG if symptomatic.
* Assess for dyspnea.
## Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor, unlike clopidogrel. This reversibility may be beneficial in patients requiring urgent surgery.
* The maintenance dose for ACS patients is 90 mg BID for 12 months. For patients with a history of MI, the dose reduces to 60 mg BID after the initial 12 months.
* Aspirin is recommended as maintenance therapy in addition to ticagrelor. The dose of aspirin should be individualized. Higher maintenance doses of aspirin (>100 mg) may reduce ticagrelor's efficacy and should be avoided.
* Discontinuation of ticagrelor prematurely increases the risk of thrombotic events.
* Ticagrelor can cause significantly elevated serum creatinine levels, which is typically not indicative of renal injury.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and professional guidelines before making clinical decisions.
